Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.45 |
| ▸ | RARB | P10826 | 11/20 | 0.45 |
| ▸ | RXRB | P28702 | 10/20 | 0.45 |
| ▸ | RARG | P13631 | 10/20 | 0.45 |
| ▸ | RXRG | P48443 | 6/20 | 0.45 |
| ▸ | RARA | P10276 | 8/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893588 | 1.00 | RXRA (0.45) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL26923655 | 0.85 | RARB (0.54) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL8690816 | 0.83 | CA1 (0.50) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL5846449 | 0.78 | RARB (0.59) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL6293921 | 0.77 | RXRA (0.40) | RXRARXRBRXRG | |
| SCHEMBL30061153 | 0.75 | CA2 (0.34) | RXRATSHR | |
| SCHEMBL6221043 | 0.75 | RARB (0.49) | RARBRARGRARA | |
| SCHEMBL17327799 | 0.75 | RARA (0.46) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL25119062 | 0.73 | ENPP2 (0.39) | TSHR | |
| SCHEMBL12120055 | 0.73 | CA2 (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | claimed |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-18 | — | — | US | claimed |
| US-12552818-B2 | Polycyclic compounds for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2026-02-17 | — | — | US | disclosed |
| EP-4519383-B1 | CYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250295028-A1 | CYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2025-09-18 | — | — | US | disclosed |
| US-20250228121-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4410074-B1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4330257-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240309033-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-09-19 | — | — | US | disclosed |
| US-20240246983-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-20240199667-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-06-20 | — | — | US | disclosed |
| US-7148245-B2 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-12-12 | — | — | US | disclosed |
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT | 2004-02-12 | — | — | US | disclosed |
| US-6649612-B1 | Combating skin ageing and keratinization | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-18 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | disclosed |
| US-6316009-B1 | FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-11-13 | — | — | US | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | RXRA 196/4885RARB 529/4885RXRB 238/4885 |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | RXRA 3/4885RARB 5/4885RXRB 2/4885 |
| US-12552818-B2 | Polycyclic compounds for organic electroluminescent devices | SCO2, ESRRA, LBR | RXRA 344/4885RARB 609/4885RXRB 383/4885 |
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | AHR, TYR, CYP1A1 | RXRA 19/4885RARB 26/4885RXRB 16/4885 |
| US-20240199667-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | RER1, RO60, RECQL | RXRA 338/4885RARB 574/4885RXRB 307/4885 |
| US-20250295028-A1 | CYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | VDAC2, VDAC3, CYCS | RXRA 3574/4885RARB 2907/4885RXRB 3910/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | RXRA 55/4885RARB 93/4885RXRB 91/4885 |
| US-20240309033-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | CRY1, LAGE3, LEF1 | RXRA 3118/4885RARB 2704/4885RXRB 3769/4885 |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | RXRA 3/4885RARB 5/4885RXRB 2/4885 |
| US-20240246983-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | NES, NUDC, NCL | RXRA 4380/4885RARB 4086/4885RXRB 4447/4885 |
| US-20250228121-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, EBPL, OCIAD2 | RXRA 473/4885RARB 1058/4885RXRB 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.